Compare

CBL-514 vs TB-500

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

CBL-514

1416 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 60% · Mixed 32% · Unfavorable overall 8%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Digestive comfort
91
Skin appearance
111
Appetite control
136
Energy
95
Mood
44

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Flushing
187
Headache
191
GI discomfort
101
Dizziness
90
Fatigue
44

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 0–1000 mcg

0–10
2
10–25
6
25–50
11
50–100
17
100–200
28
200–400
19
400–600
11
600–1000
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing20stacking38side effects26cbl-51424

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 34% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 14 days · Based on 312 repeat reporters

TB-500

486 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 60% · Mixed 26% · Unfavorable overall 14%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Sleep quality
-43
Lean mass
-153
Joint comfort
-144
Recovery
-98
Digestive comfort
-47

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Water retention
-127
Appetite loss
-73
Injection site reaction
1
Anxiety
-102
Flushing
-48

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.1–2 mg

0.1–0.2 mg
8
0.2–0.4 mg
16
0.4–0.6 mg
19
0.6–1 mg
14
1–2 mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing50stacking38side effects26tb-50019

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 34% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 14 days · Based on 107 repeat reporters

Sources (19)

Published sources linked on the CBL-514 and TB-500 wiki pages.

  1. PubMed

    Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study

    Gold M, Schlessinger J, Goodman GJ, et al. Aesthetic Surgery Journal. 2025

    Source
    Wiki study page →
  2. PubMed

    Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment

    Lorenc ZP, Gold M, Schlessinger J, et al. Aesthetic Surgery Journal. 2026

    Source
    Wiki study page →
  3. PubMed

    Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction

    Goodman GJ, Ho WWS, Chang KJ, et al. Aesthetic Surgery Journal. 2022

    Source
    Wiki study page →
  4. PubMed

    Efficacy and safety of CBL-514 for Dercum disease lipomas: A randomized phase 2a study

    Herbst KL, Ling YF, Sheu AY, et al. JAAD International. 2026

    Source
    Wiki study page →
  5. ClinicalTrials.gov

    SUPREME-01 (NCT07140939): Phase 3 CBL-514 for abdominal subcutaneous fat

    ClinicalTrials.gov. Clinical trial registry. 2026

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    SUPREME-02 (NCT07526974): Phase 3 CBL-514 for abdominal subcutaneous fat

    ClinicalTrials.gov. Clinical trial registry. 2026

    Source
    Wiki study page →
  7. Manufacturer

    Caliway Announces First Patient Dosed in Global Phase 3 SUPREME-01 Trial of CBL-514

    Caliway Biopharmaceuticals. Company press release. 2026

    Source
    Wiki study page →
  8. Manufacturer

    Caliway Highlights Global Phase 3 Progress and GLP-1 Combination Strategy (Aug 31, 2026 Investor Conference)

    Caliway Biopharmaceuticals. Company press release. 2026

    Source
    Wiki study page →
  9. Manufacturer

    Caliway Completes U.S. FDA IND Submission for SUPREME-02 Phase 3 Study of CBL-514

    Caliway Biopharmaceuticals. Company press release. 2026

    Source
    Wiki study page →
  10. FDA Drug Label

    KYBELLA (deoxycholic acid) injection — Prescribing Information

    Allergan. FDA Drug Label. 2015

    Source
    Wiki study page →
  11. Review Article

    An experimental drug kills fat cells, rather than shrinking them

    Tina Hesman Saey, Science News. Science News. 2026

    Source
    Wiki study page →
  12. Review Article

    CBL-514 injection reduces visceral and subcutaneous fat in trials

    News-Medical.net. Conference news summary. 2026

    Source
    Wiki study page →
  13. PubMed

    Thymosin beta 4 and wound healing: a multifunctional peptide

    Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010

    Source
    Wiki study page →
  14. PubMed

    Myocardial regeneration: expanding the repertoire of thymosin β4 in the ischemic heart

    Smart N, Riley PR. Ann N Y Acad Sci. 2012

    Source
    Wiki study page →
  15. ClinicalTrials.gov

    Thymosin beta-4 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  16. PubMed

    Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications

    Goldstein AL, Hannappel E, Sosne G, et al. Expert opinion on biological therapy. 2012

    Source
    Wiki study page →
  17. PubMed

    Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing

    Li X, Zheng L, Peng F, et al. Protein expression and purification. 2007

    Source
    Wiki study page →
  18. PubMed

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026

    Source
    Wiki study page →
  19. PubMed

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

    Rahman OF, Lee SJ, Seeds WA. JAAOS Glob Res Rev. 2026

    Source
    Wiki study page →